Found: 1
Select item for more details and to access through your institution.
Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 194, doi. 10.1007/s10637-014-0170-x
- By:
- Publication type:
- Article